Has Mark Kozak, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,525 in general payments to Mark Kozak, MD across 161 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Kozak, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Kozak, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Kozak, MD

Interventional Cardiology · Hershey, PANPI 1477501146

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,258 of the $3,525 with a category attached, or 64.1%. Edwards Lifesciences accounts for 73.3% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $2,193, 6.9 times the $316 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in PA, where the typical reported total is $6,486.

$3,525in general payments, 2019–2025

Across 161 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Edwards Lifesciences$3K
Abbott$137
Boston Scientific$118
Ancora Heart, Inc.$118
Asahi Intecc USA, Inc.$116
Shockwave Medical, Inc$94
plus $359 from 8 others

$337,870in research payments, 2019–2025

Across 150 payments — averaging $2252.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Edwards Lifesciences$171K
Abbott$94K
Novartis$64K
Daiichi Sankyo Inc.$9K

What the payments were for

Travel & lodging$1,26736%
Food & beverage$2,25864%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Edwards Lifesciences	137	$2,584
Abbott	3	$137
Boston Scientific	3	$118
Ancora Heart, Inc.	1	$118
Asahi Intecc USA, Inc.	1	$116
Shockwave Medical, Inc	1	$94
Teleflex LLC	1	$85
Medtronic(2 entities)	5	$69
Stryker	1	$49
Atricure, Inc.	1	$45
Cardiva Medical, Inc.	2	$43
Getinge USA Sales, LLC	2	$32
Philips North America LLC	1	$25
Cvrx, Inc.	2	$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,525 in reported general payments places this provider in the 30th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$67,340

Medicare patients

169

Services billed

318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	43	$58,973
EntrestoSacubitril/Valsartan	19	$21,962
Repatha SureclickEvolocumab	26	$13,629
Ezetimibe	39	$1,266
Metoprolol Succinate	51	$1,105
Isosorbide Mononitrate ErIsosorbide Mononitrate	31	$983
Rosuvastatin Calcium	54	$926
Eplerenone	17	$919
Atorvastatin Calcium	44	$853
ClopidogrelClopidogrel Bisulfate	27	$405
Amlodipine Besylate	37	$386
Furosemide	30	$372
Indapamide	13	$330
Losartan Potassium	34	$247
Lisinopril	19	$234

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Hershey

Alon YarkoniHershey$108K
Nishant SethiScranton$1.3M
Matthew BeckerErie$1M
William GrayWynnewood$753K
Jon GeorgePhiladelphia$637K
Shailendra SinghAllentown$470K
Sanjog KalraPhiladelphia$444K
James HarveyChambersburg$442K
Taisei KobayashiPhiladelphia$384K
Antonis PratsosBroomall$377K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →